Moreover, our results highlight other features in BC-PDMs characteristic of different BC subtypes as previously described, including hormone-receptor expression in HR+ BC-PDMs compared with TNBC -PDMs, increased collagen deposition in ILC derived BC-PDMs [37], heterogenous expression profiles of luminal (CK18) and basal cell markers (CK5 and CK6) [44] with decreased CK18 expression in TNBC -PDMs [49], and high FAPα expression in ILC BC-PDMs [52]. The gene discussed is NR4A1; the disease is breast cancer.